Tag Archives: non-muscle-invasive bladder cancer

AstraZeneca’s Imfinzi Plus BCG Induction and Maintenance Therapy Significantly Improves Disease-Free Survival in High-Risk Non-Muscle-Invasive Bladder Cancer

(IN BRIEF) The POTOMAC Phase III trial results show that adding Imfinzi to standard BCG induction and maintenance therapy improves disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). The combination demonstrated significant benefits over BCG alone, with … Read the full press release